Saskatchewan Expands Cystic Fibrosis Drug Coverage

			July 19, 2022 |  9:23 am 			

Saskatchewan is expanding coverage for Trikafta, a cystic fibrosis (CF) drug. From August 1, Trikafta will be available to CF patients six years of age and older who meet the medical criteria. “We are pleased to expand coverage of this treatment for Saskatchewan children with cystic fibrosis,” said Health Minister Paul Merriman. “We know that Tricafta has been shown to improve patients’ quality of life, and this expanded coverage will help children with CF and their families for years to come.” Trikafta targets specific genetic mutations that cause CF. this mutation affects about 90 percent of cystic fibrosis patients. “Today’s news will change the trajectory of the disease and the future for many children in Saskatchewan living with cystic fibrosis,” said Cystic Fibrosis Canada President and CEO Kelly Grover. “Saskatchewan was one of the first provinces to fund the drug for people age 12 and older last year, and today it continued to recognize the extraordinary, transformative value of Trikafta by expanding Trikafta coverage to include children ages six to 11. We celebrate this news with our CF community in Saskatchewan, who have worked tirelessly for this day.”

title: “Saskatchewan Expands Cystic Fibrosis Drug Coverage " ShowToc: true date: “2022-11-30” author: “Georgina Auld”

			July 19, 2022 |  9:23 am 			

Saskatchewan is expanding coverage for Trikafta, a cystic fibrosis (CF) drug. From August 1, Trikafta will be available to CF patients six years of age and older who meet the medical criteria. “We are pleased to expand coverage of this treatment for Saskatchewan children with cystic fibrosis,” said Health Minister Paul Merriman. “We know that Tricafta has been shown to improve patients’ quality of life, and this expanded coverage will help children with CF and their families for years to come.” Trikafta targets specific genetic mutations that cause CF. this mutation affects about 90 percent of cystic fibrosis patients. “Today’s news will change the trajectory of the disease and the future for many children in Saskatchewan living with cystic fibrosis,” said Cystic Fibrosis Canada President and CEO Kelly Grover. “Saskatchewan was one of the first provinces to fund the drug for people age 12 and older last year, and today it continued to recognize the extraordinary, transformative value of Trikafta by expanding Trikafta coverage to include children ages six to 11. We celebrate this news with our CF community in Saskatchewan, who have worked tirelessly for this day.”